Ever Supreme Bio Technology Co., Ltd. 6712

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR-T cell therapy for cancer, has successfully cleared review by the Safety Monitoring Committee (SMC). Following a thorough evaluation of the Phase I safety profile and preliminary efficacy data, the committee has greenlit the advancement to the Phase IIa clinical trial. This milestone marks the successful completion of the critical safety assessment dur